New progress in the research of protein structure and function under confinement domains

Recently, Li Conggang study group from Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences have made new progress in the research of protein structure and function under confinement domains. The results of the study are published in the journal Angew. Chem. Int. Ed, which also has other studies on recombinant rat proteins.

The confinement environment exists commonly in cells, such as molecular chaperone protein GroEL, ribosome peptide chain channel molecular machinery and a variety of organelle membrane gaps. It has been shown that confinement environments have an effect on the folding and stability of protein, but the effect of confinement conditions on the structure and function of multi-domain proteins is poorly understood.

Nuclear magnetic resonance spectroscopy is the most powerful means to obtain high resolution structures and functions of protein in complex environments. Researchers have used NMR to study the structure and function of the important signal transduction protein, calmodulin in simulated confinement environments.

The results showed that: 1) The structure of calmodulin was significantly different from that in dilute solution, in which calmodulin mainly existed in stretched structure and compact spherical structure in confined environment; 2) Calmodulin can interact with MLCK peptide, AcN19 peptide and somatostatin peptide. While in calm environment, calmodulin can bind to MLCK and AcN19 peptide and hardly bind to somatostatin peptide. Further studies have shown that the reason for the difference in function between the two environments is the spatial volume effect, not the difference in affinity. This study analyzes the high-resolution structure of the double-domain proteins in the first confinement environment, providing a structural basis for understanding the environmental effects of protein functions. At the same time, the study suggests that cells may use the restricted environment to regulate the function of some biological macromolecules.

Assistant researcher Xu Guohua and Ph.D. candidate Cheng Kayi are the co-authors of this article, and researcher Li Conggang is the communication contact person. Cusabio provides you with high-quality recombinant proteins such as recombinant CDH11 at competitive prices.

The new inhibition function of NOX4 protein in liver cancer

Researchers at the Bellvitge Institute for Biomedical Research (IDIBELL) in collaboration with King's College London have revealed the role of NADPH oxidase NOX4 as an inhibitor of epithelial amebiasis. This process helps tumor cells migrate and invade. The study was recently published in the journal Oncogene, which also publishes other studies on recombinant human proteins.

In previous studies, the researchers suggested that NOX4 acts as a tumor suppressor in the liver by inhibiting cell proliferation. "In this work, we demonstrate that NOX4 is also an important inhibitor of the invasion and metastasis of liver tumor cells," explains Dr. Isabel Fabregat, leader of the IDIBELL study group.

In-vitro studies have shown that NOX4 silencing in liver tumor cells induces amoeba migration motility. Deformation motions associated with cell shrinkage are regulated by the Rho family of proteins, and the increased expression leads to this type of movement, which is associated with aggressive metastasis.

In patients with hepatocellular carcinoma, a large number of cases were observed in the absence of NOX4. In addition, those patients with lowly-expressed NOX4 and highly-expressed Rho protein had worse prognosis. "This translates our in-vitro studies into translational correlates because it brings new prognostic biomarkers for this type of cancer," said IDIBELL.

NOX4 is regulated at the transcriptional level of TGF-β cytokines, which has been studied by the group for 15 years. TGF-β is known to be a tumor suppressor at an early stage, but it becomes an inducer at an advanced stage. According to previous studies by this group, when the expression level of NOX4 was high, TGF-β showed as inhibitors, so the use of inhibition of TGF-β drugs would be counterproductive. This study suggests that this type of drug can be an ideal candidate for patients when NOX4 is expressed at low levels and the expression level of Rho protein is high. "Thus, lowly-expressed NOX4 can be used not only as a marker of poor prognosis, but also as a marker for the use of TGF-beta inhibitors," Dr. Fabregat concluded. Flarebio offers good-quality recombinant proteins like recombinant Nrg2 for your research.

Scientists reveal the relationship between intestinal microbes and β cells

Recently, researchers led by renowned biologist Professor Karen Guillemin at the University of Oregon have brought a great breakthrough in research. They found that growth division of β cells may be controlled by gut microbes. It is well known that β cells are the only cells capable of secreting insulin, and the importance of this finding is self-evident. It is reported that this is the first time that scientists revealed the relationship between intestinal microbes and β cells. The discovery may increase a weapon for the diagnosis and treatment of diabetes. This important study by Professor Guillemin's team has been published in the famous open-source journal eLife, which also publishes other studies on recombinant rat proteins.

Professor Guillemin's team has not yet carried out research in the human body, but they did a guided study. They found several intestinal micro-organisms in the human intestinal, and they can secrete protein like BefA protein with different similarity. Hill then treated the zebrafish with the highest and lowest similarities, and he was surprised to find that zebrafish β cells also returned to normal levels. This suggests that a similar phenomenon is most likely to occur in the human body. Professor Guillemin's team is currently conducting in-depth research.

"Our research suggests that the growth and development of animals may be dependent on the release of intestinal microbial signals," Hill said, "It is too excited to see that the intestinal microbial glucose stability in glucose plays such an important role."

"We have spent many years isolating and studying the intestinal flora of zebrafish, and our efforts have not been in vain," says Professor Guillemin. "We found BefA proteins that can regulate the growth of β cells."

For patients with type I diabetes, their onset time is very early. At that time, the β cells are very fragile and vulnerable to be attacked. If the corresponding micro-organisms are then missing, it will make the patient's condition worse. Incidence of type 1 diabetes includes genes and the environment, including environmental factors and intestinal micro-organisms. Studies have shown that human β-cells generally enter dormant period in the 5-year-old and stop the division of growth. Therefore, early use of antibiotics in newborns may increase the risk of newborns suffering from type I diabetes.

Professor Guillemin said that they currently need to work with researchers studying type 1 diabetes to study the development of BefA molecules as a potential therapeutic approach. There are already many companies in the development of microbial transplantation for the treatment of oral disease capsule, hoping that the treatment of diabetes can also use similar products. Flarebio provides you with high-quality recombinant proteins including recombinant CDH2 for your research.

To promote the timely regeneration of cells by designing stem cell strategies

A team led by the National Child Health System reports that the brain developed in newborns has certain types of immature progenitor cells that can be expanded and induced to replace brain-injured cells. In a clinical model of early brain injury through recombinant horse proteins, Sirt1 plays a key role in the regeneration of glial cells by endogenous progenitor cells after hypoxia-associated brain injury.

Dr. Vittorio Gallo, director of the National Center for Neuroscience Research in Children, said, "It's not healing. It's about regenerating the lost substance." The first step is to identify cells that can regenerate the loss and then expand its associated endogenous cell proliferation. The percentage of glial progenitor cells in total brain cells was 4 to 5. Considering that the brain consists of billions of cells, this is a considerable number. The advantage is that these progenitor cells already exist, and there is no requirement through the blood-brain barrier, and ultimately they will differentiate into oligodendrocyte white matter and mature glial. That's exactly what we want them to do.

The team found that Sirt1 is a novel modulator of basal oligodendrocyte progenitor cell (OPC) proliferation and an important regulator of neonatal white matter hypoxia. "We also clarified the mechanism by which Sirt1 targets other members of the Cdk2 signaling pathway by modulating their deacetylation, complex formation, and E2F1 release, driving the Cdk2-mediated signaling pathway," said Li-Jin Chew, Ph.D., associate professor of research at the Children's Neuroscience Research Center.

In neonates, hypoxia-induced brain damage initiates spontaneous amplification of progenitor cells but also leads to a lack of mature oligodendrocytes. Inhibition of Sirt1 expression in vitro and in vivo indicates that loss of its deacetylase activity prevents the proliferation of OPC in hypoxia while promoting maturation of oligodendrocytes, emphasizing the importance of delicate balance of Sirt1 activity between maintenance of both processes.

Time is of essence because Sirt1 plays a beneficial role in a certain place (white matter) and at a given time (immature brain continues to develop). "We saw the largest Sirt1 expression and activity in the first week of neonatal brain injury," Gallo said. "There is a very narrow window that uses the stimulus of the amplified progenitor population to target this particular molecule for repair."

The team reports that Sirt1 is a nicotinamide adenine dinucleotide-dependent class III histone deacetylase, known to be involved in normal cell development, aging, inflammatory response, energy metabolism and calorie restriction. Its activity can be regulated by inhibiting the sirtinol protein of the off-the-shelf drug sirtinol. This finding points to the potential of therapeutic interventions for diffuse white matter injury in neonates. "Ideally, we would like to be able to promote the timely regeneration of cells by designing stem cell strategies," Gallo said. By the way, Flarebio offers superior recombinant proteins such as recombinant CDH2.

To develop novel CRF1 receptor inhibitors is important to treat neuropsychiatric disorders

According to research using recombinant dog proteins, CRF mRNA and CRF are widely distributed in the central nervous system (CNS) and abundant in the hypothalamic paraventricular nucleus (PVN), brainstem, amygdala, hippocampus and neocortex. CRF is a neuropeptide containing 41 amino acids. It is a kind of hormone that regulates the hypothalamic-pituitary-adrenal (HPA) axis of the hypothalamus. It is also the key hormone of neuroendocrine regulation in stress response.

CRF receptors are mainly two seven transmembrane G protein receptors (CRF1, CRF2). CFR and CFR1 have high affinity, but the affinity for CFR2 is weak. In the human body, CFR1 includes five subtypes of α, b, c-h, i, mainly distributed in the anterior pituitary, hippocampus, cerebral cortex and amygdala. Distribution of CFR1 in the anterior pituitary promotes the release of adrenocorticotropic hormone (ACTH) in the hypothalamus, which in turn promotes the release of cortisol from the adrenal cortex; which in turn regulates glucocorticoid receptors (GRs) and mineralocorticoid receptor (MRs) and the signal cascade mediates intracellular responses to stress.

Compared to CRF1, CRF2 is confined to discrete brain regions, such as the dorsal raphe nucleus (DRN), lateral septa (LS), and periaqueductal gray (PAG). CRF2 only has three subtypes: a, b, c. Although the role of CRF2 is less than CRF1, it can antagonize the CRF1-induced stress response. The different roles of CRF1 and CRF2 are also reflected in the distribution of DRN nerve cells. CRF1 is mainly in the cell membrane, while CRF2 is mainly distributed in the cytoplasm. Tension stimulation reverses this distribution, causing CRF to stimulate DRN cells rather than inhibition.

CRF1 and CRF2 have a variety of signaling pathways, the main pathway is CRF1 and CRF2 triggering downstream cascade signals leading to G protein activation, Gαs trigger second messenger cAMP (cyclization of monophosphate), cAMP activation of cAMP protein kinase A (protein kinase A, PKA). They also activate Gαq, activating the cascade of protein kinase C (PKC) and extracellular signal-regulated kinase (ERK) - mitogen-activated protein kinase (MAPK). They can also activate the apoptotic pathway through Akt / protein kinase B, NOS-guanylate cyclase and caspase. Because of this complexity, CRF1 may exchange signals through different channels of the signal.

With the further development of psychopathology, the role of CRF gets more and more attention. Numerous studies have shown that CRF levels are high in patients with neuropsychiatric disorders (including depression, addiction disorder, post-traumatic stress disorder, irritable bowel syndrome, generalized anxiety disorder, etc.) and they also found CRF mRNA increase in the tissues in patients. Subsequent studies have shown that patients are over-expressed in CRF mRNA, resulting in excessive production of CRF. Other studies have demonstrated that increased activity of the CRF1 receptor leads to the development of certain neuropsychiatric disorders. At the same time, it was also demonstrated that specific SNPs are also associated with depression. Therefore, to develop novel CRF1 receptor inhibitors is important for the treatment of neuropsychiatric disorders. Flarebio provides you with good-quality recombinant proteins including recombinant ECE1.

Researchers are trying to control senile dementia

The Dementia Research Center in the United Kingdom is trying to make dementia as controllable as HIV, and if the results are significant, we can see results in the next few years. This research using recombinant mouse proteins can help a lot of people tide over, solving the problems that have plagued the medical profession for decades.

"Alzheimer's disease is expected to be under control in 2025," the team leader said, "And this study can also help the brain reconnect and reorganize the memory system eroded by the disease."

Famous Belgium psychiatric experts expressed the hope in an interview with the Associated Press that the treatment of this disease can be treated as the same as HIV treatment. He said, "The brain is the most flexible tissue of our body. If we can control the disease early in the disease, the brain can slowly restore the lost function." The team consists of multidisciplinary teams of doctors, biologists, engineers, and data specialists.

Scientists also said that in addition to "amyloid hypothesis", the scope of the study can be further expanded. Amyloid hypothesis is a long-standing focus of research in this field. According to the Post, the brain aggregate agglomerate abnormal protein called amyloid beta plaques, causing the disease.

These plaques are hallmarks of Alzheimer's disease, but the purpose of their existence is not known. In addition to the "amyloid hypothesis", there must be other signs. Alzheimer's disease is not just the case. It is certainly like cancer which is caused by the accumulation of complex factors.

"The team hopes to change the way people know about the disease through a multidisciplinary approach in the first year," the Financial Times reported. Flarebio offers high-quality recombinant proteins like recombinant CDH15 at competitive prices.

To treat breast cancer spread with nanoparticles

Recently, the researchers found through research using recombinant horse proteins that nanoparticles can slow tumor growth so that the treatment of breast cancer more effective, and thus treating breast cancer spread.

The journal ASC Nano published the article entitled "using pRNA nanoparticles to overcome the tamoxifen resistance of breast cancer". Scientists have developed a multi-functional RNA nanoparticle which can promote the treatment of breast cancer.

Researchers used nanosecond delivery systems to treat tumor-growing proteins called MED1 and to treat her-2-positive breast cancer. In addition, they used moxifen to make cancer cells more sensitive.

"Most breast cancers have been shown to be estrogen receptors, the anti-stimulant drug moxifen has been widely used in the treatment, but the treatment is not satisfactory. Estrogen receptor-positive tumors are unresponsive to them, or they produce drug resistance after the treatment. "In this study, we have developed an innovative design that utilizes HER2 and MED1 for these tumors," reports from the Science Daily.

The team developed the nanoparticles which can effectively link HER-2 with breast cancer cells, so MED1 will gradually reduce. Researchers use these biosafety nanoparticles for use in animals.

"These nanoparticles, combined with Moxifene, have a dramatic effect on the treatment of breast cancer, which is known to play a crucial role in the proliferation, relapse and resistance of cancer cells. Eliminating these cells represents progress, and it also provides a more ideal treatment for breast cancer patients."

Researchers also said that the new discovery will be more effective for the treatment of breast cancer. Of course, more clinical trials need to be conducted. Flarebio provides superior recombinant proteins like recombinant ECE1 for your research.